Evaluation of Anterior Tibial Translation of the Knee in Healthy Women, at Two Times of the Menstrual Cycle, on Hormonal Contraceptives or Not (FLEX)

NCT ID: NCT05177549

Last Updated: 2023-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-08

Study Completion Date

2025-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Women's participation in sports at all levels has been increasing in recent decades. Many individual and team sports are at risk of anterior cruciate ligament (ACL) injury. This injury leads to a permanent or long-lasting interruption of sports practice and to significant medical and economic expenses. Women are recognized as being more at risk of anterior cruciate ligament injury with a risk 6 times higher than men. Hyperlaxity is a risk factor for anterior cruciate ligament injury, but the pathophysiological bases are little studied. Hormonal impregnation and certain periods of the menstrual cycle (ovulatory phase) are risk factors for anterior cruciate ligament injury. It therefore seems interesting to investigators to study the influence of hormonal impregnation on ligament laxity. To date no study has investigated such a relationship.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ligament; Laxity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

on estrogen-progestin contraception

Group Type EXPERIMENTAL

Bilateral knee examination with Lachmeter®

Intervention Type OTHER

Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee

under micro-progestational contraception

Group Type EXPERIMENTAL

Bilateral knee examination with Lachmeter®

Intervention Type OTHER

Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee

without hormonal contraception

Group Type EXPERIMENTAL

Bilateral knee examination with Lachmeter®

Intervention Type OTHER

Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bilateral knee examination with Lachmeter®

Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Woman between 18 and 40 years old
* No history of surgery of the 2 lower limbs
* No change in contraceptive method in the last 6 months
* Signature of the informed consent
* Affiliation to the social security system
* To be at Day 14 of her menstrual cycle (+/-1 day) (the first day of the cycle (Day1) being considered as the first day of the menstrual period), except for those on micro-progestative contraception not regulated

By inclusion group:

\- For women without hormonal contraception: No method of contraception Or a copper intrauterine device Regular cycles of 26 to 33 days

\- For women on estrogen-progestin contraception: Correct use of the estrogen-progestin pill according to the MA Or wearing a vaginal ring according to the MA protocol Or wearing a contraceptive skin patch according to the MA protocol Regular cycles of 26 to 33 days

\- For women on micro-progestin contraception : Continuous use of the micro-progestogen pill Or wearing a subcutaneous hormonal implant,

Exception: women on micro-progestin contraception who are not regulated:

* They may have an irregular cycle or no cycle to be included
* They can be included on any day if they have no cycle

Exclusion Criteria

* Pregnancy or breastfeeding in progress
* Hormonal intrauterine device or injectable contraception
* Menopause (defined as no menstruation for one year)
* Surgery: tubal ligation, oophorectomy, adnexectomy, hysterectomy
* History of microcrystalline or infectious pathology localized to the knee
* History of systemic or localized inflammatory joint disease of the knee
* History of fracture, severe sprain or dislocation of the knee joint
* History of osteoarticular or congenital diseases that may lead to laxity (Marfan syndrome, trisomy 21, Ehlers-Danlos syndrome...)
* Sign of hyperlaxity evaluated by a Beighton score higher than 4 (see appendix)
* BMI \> 25
* Daily alcohol consumption above the thresholds recommended by Public Health in France (more than 2 glasses per day)
* Woman unable to understand the protocol
* Intense or unusual physical exercise during the last 72 hours (e.g.: marathon, triathlon, competitive cycling race...)
* Woman under guardianship, curatorship or deprived of liberty
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nice

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christian ROUX

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Universitaire de Nice

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Nice

Nice, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christian ROUX

Role: CONTACT

04 92 03 92 20 ext. +33

Jerome DELOTTE

Role: CONTACT

04 92 03 61 08 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christian Roux

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19-AOI-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Menstrual Cycle-Synced Neuromuscular Training
NCT06983184 ENROLLING_BY_INVITATION NA